{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["58(6)"],"submitter":["Hosono T"],"funding":["Osaka University"],"pubmed_abstract":["<h4>Background</h4>Digital therapeutics (DTx) have attracted attention as the substitutes or add-ons to conventional pharmacotherapy and the number of DTx products authorized with the regulatory reviews of the clinical evidence is increasing. Insomnia is one of the major targets of the DTx due to the benefit from cognitive behavioral interventions and several products have been launched in the market with regulatory reviews. However, common features of the products and the clinical evidence required by each regulatory agency have not been investigated.<h4>Methods</h4>In this study, we identified the DTx products with the primary indication of insomnia authorized with regulatory reviews of clinical evidence by literature and website searches, and investigated the common features of the prod"],"journal":["Therapeutic innovation & regulatory science"],"pagination":["1138-1147"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11530488"],"repository":["biostudies-literature"],"pubmed_title":["Comparison of Product Features and Clinical Trial Designs for the DTx Products with the Indication of Insomnia Authorized by Regulatory Authorities."],"pmcid":["PMC11530488"],"pubmed_authors":["Kondoh M","Niwa Y","Hosono T"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of Product Features and Clinical Trial Designs for the DTx Products with the Indication of Insomnia Authorized by Regulatory Authorities.","description":"<h4>Background</h4>Digital therapeutics (DTx) have attracted attention as the substitutes or add-ons to conventional pharmacotherapy and the number of DTx products authorized with the regulatory reviews of the clinical evidence is increasing. Insomnia is one of the major targets of the DTx due to the benefit from cognitive behavioral interventions and several products have been launched in the market with regulatory reviews. However, common features of the products and the clinical evidence required by each regulatory agency have not been investigated.<h4>Methods</h4>In this study, we identified the DTx products with the primary indication of insomnia authorized with regulatory reviews of clinical evidence by literature and website searches, and investigated the common features of the prod","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-05T09:12:12.315Z","creation":"2025-04-05T09:12:12.315Z"},"accession":"S-EPMC11530488","cross_references":{"pubmed":["39306603"],"doi":["10.1007/s43441-024-00684-9"]}}